Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer

被引：0
作者：
David D’Andrea
Francesco Soria
Anne J. Grotenhuis
Eugene K. Cha
Nuria Malats
Savino Di Stasi
Steven Joniau
Tommaso Cai
Bas W. G. van Rhijn
Jaques Irani
Jeffrey Karnes
John Varkarakis
Jack Baniel
Joan Palou
Marek Babjuk
Martin Spahn
Peter Ardelt
Renzo Colombo
Vincenzo Serretta
Guido Dalbagni
Paolo Gontero
Riccardo Bartoletti
Stephane Larré
Per-Uno Malmstrom
Richard Sylvester
Shahrokh F. Shariat
机构：
[1] Medical University of Vienna,Department of Urology, Comprehensive Cancer Center
[2] University of the Studies of Turin,Division of Urology
[3] AOU Città Della Salute e Della Scienza di Torino,Department of Urology
[4] Radboud University Nijmegen Medical Centre,Department of Urology
[5] Weill Medical College of Cornell,Department of Urology
[6] University,Genetic and Molecular Epidemiology Group
[7] Memorial Sloan Kettering Cancer Center,Department of Urology
[8] Spanish National Cancer Research Centre (CNIO),Oncologic and Reconstructive Urology, Department of Urology
[9] Policlinico Tor Vergata-University of Rome,Department of Urology
[10] University Hospitals Leuven,Department of Surgical Oncology (Urology)
[11] Santa Chiara Hospital,Department of Urology
[12] Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital,Department of Urology
[13] Centre Hospitalier Universitaire La Milétrie,Department of Urology
[14] University of Poitiers,Department of Urology
[15] Mayo Clinic,Department of Urology, Fundacio Puigvert
[16] Sismanoglio Hospital,Department of Urology
[17] University of Athens,Department of Urology
[18] Rabin Medical Centre,Department of Urology
[19] University of Barcelona,Departement of Urology
[20] Motol Hospital,Department of Surgical, Oncological and Stomatological Sciences
[21] University of Praha,Department of Translational Research and New Technologies
[22] University Hospital of Wuerzburg,Department of Urology
[23] Universitätsklinik Freiburg,Department of Urology
[24] Università Vita Salute,Department of Urology, Second Faculty of Medicine
[25] Ospedale S. Raffaele,Institute for Urology and Reproductive Health
[26] University of Palermo,Department of Urology
[27] University of Pisa,undefined
[28] CHU de Reims,undefined
[29] Academic Hospital,undefined
[30] Uppsala University,undefined
[31] European Association of Urology Non-Muscle Invasive Bladder Cancer Guidelines Panel,undefined
[32] Charles University,undefined
[33] I.M. Sechenov First Moscow State Medical University,undefined
[34] University of Jordan,undefined
[35] European Association of Urology Research Foundation,undefined
来源：
World Journal of Urology | 2021年 / 39卷
关键词：
Bladder cancer; BCG; Response; Age; Progression; Recurrence;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3337 / 3344
页数：7
相关论文
共 96 条
  • [1] Chang SS(2016)Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline J Urol 196 1021-1029
  • [2] Boorjian SA(2019)European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)—2019 Update Eur Urol 76 639-657
  • [3] Chou R(2015)Improving selection criteria for early cystectomy in high-grade T1 bladder cancer: a meta-analysis of 15,215 patients J Clin Oncol 33 643-650
  • [4] Babjuk M(2015)Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with bacillus Calmette–Guérin: results of a retrospective multicenter study of 2451 patients Eur Urol 67 74-82
  • [5] Burger M(2009)Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette–Guerin: the CUETO scoring model J Urol 182 2195-2203
  • [6] Compérat EM(2016)EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non–muscle-invasive stage Ta–T1 urothelial bladder cancer patients treated with 1–3 years of maintenance bacillus Calmette–Guérin Eur Urol 69 60-69
  • [7] Martin-Doyle W(2017)Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency Cancer Cell 32 701-715.e7
  • [8] Leow JJ(2018)Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: a clinical decision-making tool Urol Oncol Semin Orig Investig 36 239.e1-239.e7
  • [9] Orsola A(2018)Micropapillary urothelial carcinoma of the bladder: a systematic review and meta-analysis of disease characteristics and treatment outcomes Eur Urol 75 649-658
  • [10] Gontero P(2017)Characteristics and clinical significance of histological variants of bladder cancer Nat Rev Urol 14 651-668
12345678910